Arvind Vasudeva is new CEO of Aurobindo Pharma

Our Bureau
Comment   ·   print   ·  
Arvind Vasudeva
BL Arvind Vasudeva

Aurobindo Pharma Ltd has appointed Arvind Vasudeva as Chief Executive Officer for its formulations division.

The Hyderabad-based pharma major in an announcement to the stock exchanges said his appointment will be effective from November 22.

Arvind Vasudeva served as Chief Operating Officer at Glenmark Pharmaceuticals prior to joining Aurobindo Pharma. He was instrumental in the growth of the company there. He also worked as the Managing Director of RPG Life Sciences Ltd. In addition, he also was President-Indian operations as well as Japan and ROW markets in Wockhardt.

Arvind, an M. Pharm (Pharmaceutical Technology) from Punjab University, Chandigarh, has three decades of experience in the formulations sales and marketing. “His expertise, professional capabilities and leadership will help the company strengthen its position in the pharma space further,” said K. Nithyananda Reddy, Vice-Chairman, Aurobindo Pharma, in a statement.

Incidentally, on November 9, the company had accepted the resignation of Ravindra Y. Shenoy, Joint Managing Director, who resigned due to personal reasons. N. Govindrajan is the Managing Director at present.

Meanwhile, the company’s scrip lost Rs 2.25 or 1.26 per cent on the bourses to close at Rs 176.40.

(This article was published on November 23, 2012)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.


This article is closed for comments.
Please Email the Editor
Today's Poll
Will the land bill help in rural industrialisation?
Can't Say


Exchange Rate

Dollar Spot Forward Rate

Open-Ended Mutual Funds

MCX-SX Currency Futures

NSE Currency Futures



Recent Article in Companies

Lord Bamford, Chairman

Construction equipment major JCB upbeat on govt’s infrastructure push

Expects India to become its largest revenue market by 2018 »

Comments to: Copyright © 2015, The Hindu Business Line.